Featured Pharma Online Editorial

1. Bayer Adds A Spine To Modularity For Scale Without Disruption 7/16/2026

   Modular facility concepts offer a different path, giving manufacturers the ability to expand capacity stepwise, standardize core infrastructure, and adapt production environments as product portfolios evolve

2. [VIDEO] GLP-1 Manufacturing's New Bottlenecks At Multi-Ton Scale 6/24/2026

   “At multi-ton scale, the challenge becomes less about making the molecule and more about controlling the variability of the process in this interconnected system,” explained Villain.

3. Can Molecular Glue Degraders Make The Undruggable Druggable? 6/12/2026

   Neomorph CEO Phil Chamberlain explains how molecular glue degraders could expand the druggable proteome and why the modality’s small-molecule profile may matter as much as its novel mechanism.

4. Chugai Accelerates Automation To Boost Operational Efficiency 6/3/2026

   What do you do when tasked with producing drugs of different molecular sizes, including highly potent compounds, in the same facility on a global scale? You tap technological advances in automation, modular design for flexibility, and tie it together with systems that enable real-time data.

5. The Future Of Continuous Is Integrated Manufacturing: The 4 Misconceptions About A Lean Process 6/2/2026

   Pharmaceutical continuous manufacturing is an enabler of better manufacturing, but only when implemented with intention.

6. Why Isolators Do Not Automatically Ensure Annex 1 Compliance 5/12/2026

   Isolators are powerful tools, but they do not automatically ensure compliance with EU GMP Annex 1. RABS are frequently dismissed too quickly. The difference is not the technology itself, but how it is applied.

7. How Generic Pharma Manufacturers Can Rebuild Margins Inside The Four Walls 5/4/2026

   The pricing dynamics for generic drugs turns formerly attractive products into high-volume, low-margin commodities. Lean and Six Sigma in four key areas can unlock efficiencies.

8. Making Mental Health Drugs: Promising Therapies And Manufacturing Challenges 4/30/2026

   Psychedelic therapies have shown promise in treating mental health disorders, but it will take close collaboration and cooperation of all related agencies and manufacturers to make this promise a reality.

9. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

   Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.

10. 4 Facility Considerations for API Manufacturing 3/25/2026

    Success depends not only on equipment and infrastructure, but also on specialized workforce training, rigorous quality control, robust data management, and increasingly sophisticated supply chain and manufacturing technologies.